Pre-made Radretumab benchmark antibody ( di-scFv + CH4, anti-FN extra domain B therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.
| Products Name (INN Index) | Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody |
|---|---|
| INN Name | Radretumab |
| Target | FN extra domain B |
| Format | di-scFv + CH4 |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgE |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Philogen |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Brain cancer,Non-small cell lung cancer,Solid tumours,Haematological malignancies,Hodgkin's disease |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FN extra domain B |
| Package |
